Author:
Qin Yiyang,Sekine Ikuo,Fan Mengmeng,Takiguchi Yuichi,Tada Yuji,Shingyoji Masato,Hanazono Michiko,Yamaguchi Naoto,Tagawa Masatoshi
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference23 articles.
1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of PEM in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.
2. Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H, et al. An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol. Springerplus. 2016;5:195.
3. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Dev Ther. 2016;10:1885–9.
4. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007;26:153–81.
5. McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res. 2000;6:2677–84.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献